<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1012435</article-id><article-id pub-id-type="publisher-id">ACM-39107</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201200000_52661821.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  胶质母细胞瘤的治疗现状
  Current Status of Glioblastoma Treatment
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>壮</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>军</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>苏</surname><given-names>文</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>滨州医学院烟台附属医院神经外科，山东 烟台</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>12</month><year>2020</year></pub-date><volume>10</volume><issue>12</issue><fpage>2875</fpage><lpage>2882</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    背景：胶质瘤是人类最常见的脑瘤。胶质母细胞瘤又称多形性胶质母细胞瘤(glioblastoma multiforme, GBM，简称胶母)是最常见、最具侵袭性的胶质瘤之一，占原发性脑肿瘤的52%，占所有颅内肿瘤的20%。在欧洲和北美，GBM的发病率为2~3/10万人。GBM患者预后较差，中位生存期(MS)保持在12~15个月之间，从诊断开始的5年生存率低于5%。GBM的标准治疗包括手术、放疗、化疗和综合治疗。然而，新诊断的GBM患者的MS在过去10年中只有轻微的改善。目的：对胶质母细胞瘤的最新治疗现状进行综述。方法：通过检索近几年PubMed数据库、中国知网等中英文期刊全文数据库相关内容文章，并系统整理相关重要文献进行综述。结果与结论：目前的治疗方法均不能彻底治愈GBM患者，只能延长其生存期。随着肿瘤基因层面的进展以及最佳联合治疗方式的进一步研究，GBM患者的预后将会更加光明。
    BACKGROUND: Glioma is the most common brain tumor in humans. Glioblastoma Multiforme (GBM) is one of the most common and aggressive gliomas, accounting for 52 percent of primary brain tumors and 20 percent of all intracranial tumors. In Europe and North America, the incidence of GBM is 2 - 3 per 100,000 people. GBM patients have a poor prognosis, the median survival (MS) remains between 12 - 15 months, and the 5-year survival rate from diagnosis is less than 5%. Standard treatment for GBM includes surgery, radiotherapy, chemotherapy, and combination therapy. However, MS in newly diagnosed GBM patients has improved only slightly in the past 10 years. OBJECTIVE: To review the latest treatment of glioblastoma. METHODS: By retrieving the articles related to the full-text databases of Chinese and English periodicals such as PubMed database and CNKI in recent years, and systematically sorting out the relevant important literatures for review. RESULTS AND CONCLUSION: Current treatment methods cannot completely cure GBM patients, only to prolong their survival. With the progress of tumor gene level and further research on the best combination therapy, the prognosis of GBM patients will be brighter. 
  
 
</p></abstract><kwd-group><kwd>胶质母细胞瘤，化疗，免疫治疗，肿瘤电场治疗，光动力疗法, Glioblastoma</kwd><kwd> Chemotherapy</kwd><kwd> Immunotherapy</kwd><kwd> Tumor Treating Fields</kwd><kwd> Photodynamic Therapy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>背景：胶质瘤是人类最常见的脑瘤。胶质母细胞瘤又称多形性胶质母细胞瘤(glioblastoma multiforme, GBM，简称胶母)是最常见、最具侵袭性的胶质瘤之一，占原发性脑肿瘤的52%，占所有颅内肿瘤的20%。在欧洲和北美，GBM的发病率为2~3/10万人。GBM患者预后较差，中位生存期(MS)保持在12~15个月之间，从诊断开始的5年生存率低于5%。GBM的标准治疗包括手术、放疗、化疗和综合治疗。然而，新诊断的GBM患者的MS在过去10年中只有轻微的改善。目的：对胶质母细胞瘤的最新治疗现状进行综述。方法：通过检索近几年PubMed数据库、中国知网等中英文期刊全文数据库相关内容文章，并系统整理相关重要文献进行综述。结果与结论：目前的治疗方法均不能彻底治愈GBM患者，只能延长其生存期。随着肿瘤基因层面的进展以及最佳联合治疗方式的进一步研究，GBM患者的预后将会更加光明。</p></sec><sec id="s2"><title>关键词</title><p>胶质母细胞瘤，化疗，免疫治疗，肿瘤电场治疗，光动力疗法</p></sec><sec id="s3"><title>Current Status of Glioblastoma Treatment</title><p>Zhuang Li, Jun Yang<sup>*</sup>, Wen Su</p><p>Department of Neurosurgery, Yantai Affiliated Hospital of Binzhou Medical University, Yantai Shandong</p><p><img src="//html.hanspub.org/file/5-1571748x5_hanspub.png" /></p><p>Received: Nov. 15<sup>th</sup>, 2020; accepted: Dec. 3<sup>rd</sup>, 2020; published: Dec. 10<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/5-1571748x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>BACKGROUND: Glioma is the most common brain tumor in humans. Glioblastoma Multiforme (GBM) is one of the most common and aggressive gliomas, accounting for 52 percent of primary brain tumors and 20 percent of all intracranial tumors. In Europe and North America, the incidence of GBM is 2 - 3 per 100,000 people. GBM patients have a poor prognosis, the median survival (MS) remains between 12 - 15 months, and the 5-year survival rate from diagnosis is less than 5%. Standard treatment for GBM includes surgery, radiotherapy, chemotherapy, and combination therapy. However, MS in newly diagnosed GBM patients has improved only slightly in the past 10 years. OBJECTIVE: To review the latest treatment of glioblastoma. METHODS: By retrieving the articles related to the full-text databases of Chinese and English periodicals such as PubMed database and CNKI in recent years, and systematically sorting out the relevant important literatures for review. RESULTS AND CONCLUSION: Current treatment methods cannot completely cure GBM patients, only to prolong their survival. With the progress of tumor gene level and further research on the best combination therapy, the prognosis of GBM patients will be brighter.</p><p>Keywords:Glioblastoma, Chemotherapy, Immunotherapy, Tumor Treating Fields, Photodynamic Therapy</p><disp-formula id="hanspub.39107-formula19"><graphic xlink:href="//html.hanspub.org/file/5-1571748x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/5-1571748x8_hanspub.png" /> <img src="//html.hanspub.org/file/5-1571748x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 介绍</title><p>胶质母细胞瘤是恶性程度最高的星形细胞肿瘤，组织学上，胶质母细胞瘤是有丝分裂活跃的肿瘤，其特征是微血管增生或坏死，或两者兼有，为WHO IV级的独特形态学特征 [<xref ref-type="bibr" rid="hanspub.39107-ref1">1</xref>]。根据2016年更新的WHO分类，GBM主要分为3大类：① IDH野生型胶质母细胞瘤(约90%患者)，基本相当于临床上原发或新发胶质母细胞瘤，好发于55岁以上的患者；② IDH突变型胶质母细胞瘤(约10%患者)，近似于临床上继发于既往较低级别弥漫胶质瘤病史的胶质母细胞瘤，好发于较年轻的患者；③ NOS型胶质母细胞瘤，未进行全面IDH评估时方用此诊断 [<xref ref-type="bibr" rid="hanspub.39107-ref2">2</xref>]。一般来说，手术切除的范围直接影响生存，手术切除程度大于体积的98%和年龄低于65岁患者的生存期明显长于部分切除和年龄较大的患者，因此，手术切除程度和年龄是独立的危险因素，但是并不是所有的研究都表明大范围切除肿瘤会提高生存率，若肿瘤主体位于基底节或丘脑，则不适宜手术切除，活检更为适宜，深部胶母活检可以应用立体定向方法，对于皮质下弥漫的胶母也可以开颅活检，但是，由于肿瘤不同部位性质可能不同，活检有可能造成病理诊断错误 [<xref ref-type="bibr" rid="hanspub.39107-ref3">3</xref>]。胶母恶性程度高，生长快、病程短，不能单独依靠手术治疗，我们简单回顾了目前除手术外常见的其他一些治疗方式。</p></sec><sec id="s6"><title>2. 治疗方法</title><sec id="s6_1"><title>2.1. 放疗(Radiotherapy, RT)</title><p>在最佳手术切除后，GBM患者应在安全情况下尽早开始放射治疗。2005年，一项III期临床试验证实放疗联合TMZ化疗(称为Stupp方案)比单纯放疗更有效。接受TMZ + RT治疗的患者中位生存期(MST)为14.6个月，而单纯接受RT治疗的患者MST为12.1个月。生存优势明显存在，相比单纯放疗组，TMZ + RT组的长期存活比例更高，2年生存期分别为27%和11%，5年生存期分别为10%和2% [<xref ref-type="bibr" rid="hanspub.39107-ref4">4</xref>]。</p><p>历史上，全脑RT (WBRT)用于治疗新诊断的GBM，但WBRT存在多种潜在的长期并发症，包括内分泌疾病、神经认知障碍和RT诱发的白质脑病。这些严重的并发症促使研究探索使用受累野放疗(IFRT)以减少毒性。IFRT将外束放射治疗送到距肿瘤2~3 cm的地方，这是因为，放射治疗后，80%~90%的病例GBM复发在原肿瘤位置2 cm内 [<xref ref-type="bibr" rid="hanspub.39107-ref5">5</xref>]。20世纪70年代早期的多项研究证实，IFRT与WBRT相比具有类似或略有提高的生存优势，RT野内正常组织损伤更少。</p><p>为了改善局部控制和限制对正常脑组织的毒性，已研究了其他技术，包括碘-125腔内近距离放射治疗、立体定向放射手术(SRS)和大分割放疗(HFRT)。然而，这些并没有为新诊断的患者带来显著的生存优势。尽管对新诊断的GBM进行放疗的初步回顾性报告很有前景，但RTOG 9305 (唯一完成的SRS治疗GBM的随机研究)显示生存率无差异。因此，SRS对新诊断的GBM的作用尚未得到证实 [<xref ref-type="bibr" rid="hanspub.39107-ref6">6</xref>]。</p></sec><sec id="s6_2"><title>2.2. 替莫唑胺(Temozolomide, TMZ)</title><p>替莫唑胺是一种DNA烷化剂，靶向鸟嘌呤在O-6和N-7的位置。它阻止DNA的复制并破坏癌细胞。术后与放疗同步进行，接下来再应用6个疗程已经成为新诊断的70岁以下GBM患者的标准治疗方案 [<xref ref-type="bibr" rid="hanspub.39107-ref3">3</xref>]。在一项共有562例患者参与的试验中，随机分组，每组281例，中位年龄73岁(65~90)。放疗联合替莫唑胺组的总生存期长于单纯放疗组(9.3个月vs. 7.6个月)，无进展生存期也是如此(5.3个月vs. 3.9个月)。在165例甲基化MGMT状态的患者中，放疗联合替莫唑胺的中位总生存期为13.5个月，单纯放疗的总生存期为7.7个月。在189例非甲基化MGMT状态的患者中，放疗联合替莫唑胺的总生存期为10.0个月，单纯放疗的总生存期为7.9个月 [<xref ref-type="bibr" rid="hanspub.39107-ref7">7</xref>]。</p></sec><sec id="s6_3"><title>2.3. 卡莫司汀(Carmustine, BCNU)</title><p>通常，高级别胶质瘤的治疗标准包括大体切除、体外放射治疗和替莫唑胺(TMZ)的全身化疗。然而，安全性、血脑屏障穿透性和全身化疗的有效性构成了最佳治疗的障碍 [<xref ref-type="bibr" rid="hanspub.39107-ref8">8</xref>]。卡莫司汀(BCNU)是一种亚硝基脲类药物，通过抑制DNA的合成和修复来干预肿瘤的发生发展。为了有效地使用BCNU，可生物降解的聚合物晶片(Gliadel)被插入手术腔内，更有效地输送药物，产生比血管内给药更好的结果。然而，卡莫司汀受到表达高水平DNA修复酶的细胞的抵抗，如06 -烷基鸟嘌呤-DNA烷基转移酶(AGT)或06-甲基鸟嘌呤DNA甲基转移酶(MGMT)。所以，能够提高患者生存率的协同治疗变得非常重要。根据Stupp等人的伴随和辅助TMZ方案，将TMZ与Gliadel和放疗联合使用已经成为治疗胶质母细胞瘤的标准程序 [<xref ref-type="bibr" rid="hanspub.39107-ref9">9</xref>]。McGrit等人的报道称，在Gliadel和放射治疗的同时接受TMZ治疗可以提高中位生存期(MST)。接受TMZ治疗的两年生存率为39%，而不接受TMZ治疗的两年生存期为18% [<xref ref-type="bibr" rid="hanspub.39107-ref10">10</xref>]。但是，有研究表明，Gliadel晶片可产生严重颅内感染、颅内高压和脑脊液泄漏等并发症 [<xref ref-type="bibr" rid="hanspub.39107-ref11">11</xref>]。</p></sec><sec id="s6_4"><title>2.4. 洛莫司汀(Lomustine, CCNU)</title><p>洛莫司汀是一种硝脲类药物，首次通过肝脏后迅速羟基化为烷化代谢物，半衰期为16~48 h，血脑屏障穿透性良好。洛莫司汀与另一种烷化剂甲基苄肼和抗有丝分裂剂长春新碱作为PCV方案联合使用时，具有明显疗效。在3项WHO分级较低的胶质瘤随机临床试验中，已证实PCV方案联合放疗优于单纯放疗。从这些试验的亚组分析可以得出结论，PCV在少突胶质瘤中最活跃，其次是IDH突变型胶质母细胞瘤，而IDH野生型胶质母细胞瘤的活性尚不确定 [<xref ref-type="bibr" rid="hanspub.39107-ref12">12</xref>]。到目前为止，甲基苄肼和长春新碱在多大程度上有助于PCV方案的疗效仍然是一个争议的领域。</p><p>长春新碱不能通过血脑屏障，而且长期使用会引起周围神经病变的显著毒性，因此，有人建议将该药物从PCV方案中省略，但是，目前还没有临床试验将PCV方案与PC方案进行比较。</p><p>甲基苄肼是另一种与替莫唑胺化学相关的烷基化剂，与替莫唑胺相比，它在复发性胶质母细胞瘤中作为单一剂的活性较低。因此，有理由通过替莫唑胺取代甲基苄肼和省略长春新碱来设计新的烷基化剂组合治疗新诊断的胶质母细胞瘤。在一项小型二期试验UKT-03和三期试验CeTeG中，虽然存在患者预后因素不平衡的因素影响，但总体上仍存在替莫唑胺–洛莫司汀联合治疗较标准治疗生存期延长的信号 [<xref ref-type="bibr" rid="hanspub.39107-ref13">13</xref>]。</p><p>洛莫司汀在胶质瘤治疗中尽管有所局限性，但在欧洲(贝伐单抗未被批准)、EANO指南以及胶质母细胞瘤自适应全球创新学习环境(AGILE)联盟 [<xref ref-type="bibr" rid="hanspub.39107-ref14">14</xref>] 中，它被定义为治疗复发性胶质母细胞瘤的主要标准。此外，洛莫司汀可能是PCV方案的关键组成部分，该方案已成为大多数具有IDH突变的WHO较低级别胶质瘤的标准治疗方案。</p></sec><sec id="s6_5"><title>2.5. 贝伐珠单抗(Bevacizumab, BV)</title><p>贝伐珠单抗(BV)是一种抑制血管内皮生长因子(VEGF)的人类单克隆抗体，于2009年被美国FDA批准用于治疗复发性GBM。在一项167例患者随机参与的II期、多中心、非对比试验中评价了贝伐单抗单独和联合伊立替康治疗复发性胶质母细胞瘤患者的疗效，贝伐单抗组和贝伐单抗联合伊立替康组的6个月无进展生存期(PFS)分别为42.6%和50.3%，中位总生存期分别为9.2个月和8.7个月。贝伐单抗和贝伐单抗联合伊立替康治疗的患者中，分别有46.4%和65.8%的患者发生了3级不良事件，其中贝伐单抗组最常见的是高血压(8.3%)和惊厥(6.0%)，贝伐单抗+伊立替康组最常见的是抽搐(13.9%)、中性粒细胞减少(8.9%)和疲劳(8.9%) [<xref ref-type="bibr" rid="hanspub.39107-ref15">15</xref>]。欧洲癌症研究和治疗组织(European Organization for Research and Treatment of Cancer)对GBM首次复发患者的26101项试验中，将单药洛莫司汀与洛莫司汀加贝伐单抗进行比较。令人失望的是，联合用药组的总生存期(OS)主要终点仅为9.1个月，而洛莫司汀组为8.6个月，两者无显著差异。虽然联合方案改善了PFS，但在生活质量和神经认知功能方面，加佣贝伐珠单抗未观察到获益 [<xref ref-type="bibr" rid="hanspub.39107-ref16">16</xref>]。对于新诊断的胶质母细胞瘤，在标准治疗中加入贝伐珠单抗并不能提高总生存率，而且与早期不良事件如高血压、血栓栓塞事件等的高发生率相关。贝伐珠单抗可能有助于延长无进展生存期，但在临床实践中，贝伐珠单抗作为新诊断GBM标准治疗的常规补充并不推荐 [<xref ref-type="bibr" rid="hanspub.39107-ref17">17</xref>]。</p></sec><sec id="s6_6"><title>2.6. 免疫治疗</title><sec id="s6_6_1"><title>2.6.1. 肽疫苗</title><p>在原发性GBM和经典GBM亚型中发现的表皮生长因子受体III型突变体(EGFRvIII)等肽疫苗可触发对GBM肿瘤细胞表达的EGFRvIII的免疫。在一项有18名患者参与的II期试验中，接种EGFRvIII疫苗的患者获得了26个月的总生存期，而对照组仅显示出15个月的总生存期 [<xref ref-type="bibr" rid="hanspub.39107-ref18">18</xref>]。其他正在进行临床试验的可用疫苗包括肿瘤裂解疫苗和树突细胞疫苗(DCVax-L) [<xref ref-type="bibr" rid="hanspub.39107-ref19">19</xref>]。</p></sec><sec id="s6_6_2"><title>2.6.2. 过继细胞疗法(Adoptive Cellular Therapy, ACT)</title><p>将嵌合抗原受体(CARS)引入T细胞(CAR-T)，以理想的标记物EGFRvIII为靶点，产生肿瘤特异性T细胞 [<xref ref-type="bibr" rid="hanspub.39107-ref20">20</xref>]，已成为应用最广泛的ACT方法。I期和II期临床试验显示，在接种EGFRvIII表达的GBM肿瘤的患者中，PFS和OS (26个月vs 14.6个月)显著升高 [<xref ref-type="bibr" rid="hanspub.39107-ref21">21</xref>]。ACT的准确性在治疗GBM方面显示出很大的潜力。</p></sec></sec><sec id="s6_7"><title>2.7. 基因治疗</title><sec id="s6_7_1"><title>2.7.1. Toca 511和Toca FC</title><p>将杀肿瘤基因整合到病毒载体中的技术在肿瘤学领域已经存在了几年，其中一个例子是Toca 511和Toca FC，通过逆转录病毒复制载体来部署转基因胞嘧啶脱氨酶，该载体催化5-氟胞嘧啶形成活性5-氟尿嘧啶 [<xref ref-type="bibr" rid="hanspub.39107-ref22">22</xref>]。Toca 511/Toca FC已用于I期和II期临床试验，对高级别胶质瘤患者的生存期产生了积极结果 [<xref ref-type="bibr" rid="hanspub.39107-ref23">23</xref>]。这种逆转录病毒系统最有趣的是它不会触发宿主的免疫系统，从而使溶瘤剂得以部署并迅速在肿瘤细胞中扩散。</p></sec><sec id="s6_7_2"><title>2.7.2. AAV9-sTRAIL</title><p>用病毒基因转移技术对抗GBM的另一种方法是使用腺相关病毒(AAV)载体直接注射到GBM细胞中，以表达杀瘤作用的基因。Crommentujin等人已经证实，使用AAV9载体产生一种抗癌药物sTRAIL，与对照组相比，可杀死小鼠模型和转染细胞系中多达60% GBM细胞 [<xref ref-type="bibr" rid="hanspub.39107-ref24">24</xref>]。AAV9病毒载体因其在静脉注射时具有通过血脑屏障的血清型能力而成为病毒载体的明智选择 [<xref ref-type="bibr" rid="hanspub.39107-ref25">25</xref>]。</p></sec><sec id="s6_7_3"><title>2.7.3. 自杀基因</title><p>基因治疗的其他方法包括在单纯疱疹病毒载体中转移自杀基因(胸苷激酶)，使细胞毒性核苷类似物磷酸化。这种磷酸化反过来会导致类似物与增殖细胞的DNA结合，从而阻止细胞分裂 [<xref ref-type="bibr" rid="hanspub.39107-ref26">26</xref>]。通过非复制型5型腺病毒将外源性肿瘤抑制基因(即p53、PTEN和p16INK4A)引入GBM细胞后，细胞增殖、肿瘤发生和肿瘤进展也显著下降 [<xref ref-type="bibr" rid="hanspub.39107-ref27">27</xref>]。</p></sec></sec><sec id="s6_8"><title>2.8. 肿瘤治疗电场(Tumor Treating Fields, TTF)</title><p>TTF设备包括4个传感器阵列，每个阵列由9个绝缘电极组成，置于患者头皮以输送低强度、中频(100~300 kHz)交变电场 [<xref ref-type="bibr" rid="hanspub.39107-ref28">28</xref>]。2004年，一项临床前模型证明了TTF装置对增殖细胞的抑制作用，而非增殖细胞不受影响。TTF设备通过将微管蛋白二聚体定位在离微管生长末端更远的地方来干扰有丝分裂纺锤体微管的正常聚合和解聚 [<xref ref-type="bibr" rid="hanspub.39107-ref29">29</xref>]。从而使有丝分裂被破坏，导致有丝分裂灾难，最终导致有丝分裂细胞死亡。</p><p>测试TTF设备(EF-11)的第一阶段Ⅲ期临床试验于2012年发表，包括237名复发的GBM患者。这项研究比较了第一代TFF设备单独使用(每天佩戴18~24小时)与化疗方案。接受TTF装置治疗的患者和接受化疗的患者的MST分别为6.6个月和6.0个月(p = 0.27)。尽管该试验没有证明TTF改善总生存期，但其疗效与常用的化疗方案相似。TTF组报告了较低的毒性和更好的生活质量，包括认知改善和情绪健康。这些患者也出现了较少的化疗相关副作用，如血液毒性、胃肠道不良事件和感染 [<xref ref-type="bibr" rid="hanspub.39107-ref30">30</xref>]。这项试验的结果导致FDA于2011年批准第一代TFF设备用于治疗复发的GBM或对传统疗法无效的GBM患者 [<xref ref-type="bibr" rid="hanspub.39107-ref31">31</xref>]。</p><p>由Roger Stupp博士领导的一项针对新诊断的GBM III期临床试验(EF-14)启动，该试验报告TTF + TMZ组的OS为20.9个月，单TMZ组仅为16.0个月 [<xref ref-type="bibr" rid="hanspub.39107-ref28">28</xref>]。因此，FDA于2015年10月5日批准TTF设备用于新诊断的GBM [<xref ref-type="bibr" rid="hanspub.39107-ref31">31</xref>]。</p></sec><sec id="s6_9"><title>2.9. 光动力疗法(Photodynamic Therapy, PDT)</title><p>光动力疗法是使用一种化学物质，这种化学物质能够吸收光子，从而引发一个对肿瘤细胞有害的过程 [<xref ref-type="bibr" rid="hanspub.39107-ref32">32</xref>]。PDT需要光源、光敏剂(PS)和氧气。PS定位于靶细胞，当受到特定波长的光时，吸收光子。这会使电子进入激发态,最终引发两种类型的光化学反应。在第一类反应中，直接与生物底物的分子发生相互作用，最终导致自由基的形成。在第二种类型中，激发的PS与氧分子相互作用形成单线态氧，这对活细胞有细胞毒性，因为它是一种强大的氧化剂 [<xref ref-type="bibr" rid="hanspub.39107-ref33">33</xref>]。然而，单线态氧在短距离内扩散(0.02~1.00 &#181;m)，且寿命有限(0.04~4.0 &#181;s)，有助于局部肿瘤消融，同时最大限度地降低对邻近正常组织的损伤风险 [<xref ref-type="bibr" rid="hanspub.39107-ref34">34</xref>]。PDT对肿瘤的有害作用主要有三种机制。首先，活性氧(ROS)在细胞质或线粒体中的产生直接损伤蛋白质、脂质、DNA等分子，导致癌细胞死亡，主要是由于细胞凋亡的激活。其次，一些PDT药物可引起微血管的凝血和血栓形成，导致缺血、坏死和肿瘤浸润，这在所有5-氨基乙酰丙酸(5-ALA)的研究中都被注意到。最后，光动力疗法可以激活免疫细胞和/或刺激细胞因子，以引起对肿瘤细胞的免疫反应 [<xref ref-type="bibr" rid="hanspub.39107-ref32">32</xref>] [<xref ref-type="bibr" rid="hanspub.39107-ref35">35</xref>]。</p><p>5-ALA介导的PDT治疗胶质母细胞瘤</p><p>在一项初步研究中，对15例新诊断的小的(&lt;4 cm)和不能切除的GBM患者进行5-ALA介导的PDT治疗，并与112例接受肿瘤完全切除的GBM患者进行了比较。所有患者均接受标准放疗和替莫唑胺治疗。PDT组的PFS明显延长，分别为16.0个月和10.2个月，3年生存期分别为56.0%和21.0% [<xref ref-type="bibr" rid="hanspub.39107-ref36">36</xref>]。值得注意的是，PDT组15例患者中有6例PFS大于30个月。</p><p>HpD介导的PDT治疗胶质母细胞瘤</p><p>在一项包含78例GBM患者接受HPD介导的PDT治疗研究中，对肿瘤进行最大限度的安全切除，然后在术中进行光照射。接受PDT治疗的GBM患者的OS为14.3个月 [<xref ref-type="bibr" rid="hanspub.39107-ref37">37</xref>]。</p><p>Porfimer Sodium介导的PDT治疗胶质母细胞瘤</p><p>在49例新诊断和复发GBM瘤患者中，在最大程度的肿瘤切除后，在切除腔内放置球囊扩散器或持续输注脂肪乳剂并应用光照射。GBM患者的MST为30周，1年和2年的生存期分别为22.0%和2.0% [<xref ref-type="bibr" rid="hanspub.39107-ref38">38</xref>]。</p><p>Talaporfin Sodium介导的PDT治疗胶质母细胞瘤</p><p>在一项临床试验中，4例新诊断的GBM患者接受最大安全肿瘤切除后行Talaporfin Sodium介导的PDT治疗的MST为26.0个月(其中1例生存期 &gt; 38.0个月)，而6例复发的GBM患者接受相同治疗后的MST为8个月。Muragaki等人在一项使用Talaporfin Sodium介导的PDT治疗原发性脑肿瘤(包括13例GBM患者)研究中，所有患者在光动力疗法的基础上加用TMZ辅助化疗，其OS为24.8个月，PFS为12.0个月 [<xref ref-type="bibr" rid="hanspub.39107-ref39">39</xref>]。</p><p>Boronated Porphyrin介导的PDT治疗胶质母细胞瘤</p><p>一项I期试验评估了Boronated Porphyrin治疗高级别GBM的安全性，其中包括7名新诊断的患者和9名复发的GBM患者。新诊断的GBM患者的OS为5.0个月，而PDT后复发GBM患者的OS为11.0个月 [<xref ref-type="bibr" rid="hanspub.39107-ref40">40</xref>]。</p></sec></sec><sec id="s7"><title>3. 总结和展望</title><p>胶质母细胞瘤是一种不能单独应用手术治疗的恶性肿瘤，完整的切除肿瘤几乎不可实现，尽管采取了一系列积极的术前、术后治疗方案，但是由于肿瘤的高度异质性、侵袭性和血脑屏障的限制，今天的治疗并不能治愈GBM患者，只能延长他们的总体生存时间。因此，多靶点联合、多疗法联合以及开发新的治疗方式成为目前研究的一个热点方向，也成为医生和研究人员最具挑战性的任务。同时也需要大量的后续临床试验来证明研究的可行性和有效性。随着对肿瘤机制的进一步了解，以及最佳的联合治疗方式的发展，GBM的治疗将会有更加光明的未来。</p></sec><sec id="s8"><title>文章引用</title><p>李 壮,杨 军,苏 文. 胶质母细胞瘤的治疗现状Current Status of Glioblastoma Treatment[J]. 临床医学进展, 2020, 10(12): 2875-2882. https://doi.org/10.12677/ACM.2020.1012435</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39107-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Le Rhun, E., Preusser, M. and Roth, P. (2019) Molecular Targeted Therapy of Glioblastoma. Cancer Treatment Reviews, 80, 101896. &lt;br&gt;https://doi.org/10.1016/j.ctrv.2019.101896</mixed-citation></ref><ref id="hanspub.39107-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Louis, D.N., Perry, A., Reifenberger, G., et al. (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Summary. Acta Neuropathologica, 131, 803-820.  
&lt;br&gt;https://doi.org/10.1007/s00401-016-1545-1</mixed-citation></ref><ref id="hanspub.39107-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">王忠诚. 王忠诚神经外科学[M]. 第2版. 武汉: 湖北科学技术出版社, 2015: 515-520.</mixed-citation></ref><ref id="hanspub.39107-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Stupp, R., Hegi, M.E., Mason, W.P., et al. (2009) Effects of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-Year Analysis of the EORTC-NCIC Trial. The Lancet Oncology, 10, 459-466.</mixed-citation></ref><ref id="hanspub.39107-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Chamberlain, M.C. (2011) Radiographic Patterns of Relapse in Glioblastoma. Journal of Neuro-Oncology, 101, 319-323. &lt;br&gt;https://doi.org/10.1007/s11060-010-0251-4</mixed-citation></ref><ref id="hanspub.39107-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Jennifer, L.S., Gordon, L., Jenny, L.S., et al. (2018) Stereotactic Radiosurgery and Hypofractionated Radiotherapy for Glioblastoma. Neurosurgery, 82, 24-34. &lt;br&gt;https://doi.org/10.1093/neuros/nyx115</mixed-citation></ref><ref id="hanspub.39107-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Perry, J.R., Laperriere, N., O’Callaghan, C.J., et al. (2017) Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. The New England Journal of Medicine, 376, 1027-1037.</mixed-citation></ref><ref id="hanspub.39107-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Attenello, F.J., Mukherjee, D., Datoo, G., et al. (2008) Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience. Annals of Surgical Oncology, 15, Article No. 2887.  
&lt;br&gt;https://doi.org/10.1245/s10434-008-0048-2</mixed-citation></ref><ref id="hanspub.39107-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Bregy, A., Shah, A.H., Diaz, M.V., et al. (2013) The Role of Gliadel Wafers in the Treatment of High-Grade Gliomas. Expert Review of Anticancer Therapy, 13, 1453-1461. &lt;br&gt;https://doi.org/10.1586/14737140.2013.840090</mixed-citation></ref><ref id="hanspub.39107-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">McGirt, M.J., Than, K.D., Weingart, J.D., et al. (2009) Gliadel (BCNU) Wafer plus Concomitant Temozolomide Therapy after Primary Resection of Glioblastoma Multiforme. Journal of Neurosurgery, 110, 583-538.  
&lt;br&gt;https://doi.org/10.3171/2008.5.17557</mixed-citation></ref><ref id="hanspub.39107-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Buonerba, C., Di Lorenzo, G., Marinelli, A., et al. (2011) A Comprehensive Outlook on Intracerebral Therapy of Malignant Gliomas. Critical Reviews in Oncology/Hematology, 80, 54-68.  
&lt;br&gt;https://doi.org/10.1016/j.critrevonc.2010.09.001</mixed-citation></ref><ref id="hanspub.39107-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Buckner, J.C., Shaw, E.G., Pugh, S.L., et al. (2016) Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. The New England Journal of Medicine, 374, 1344-1355. &lt;br&gt;https://doi.org/10.1056/NEJMoa1500925</mixed-citation></ref><ref id="hanspub.39107-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Weller, M. and Rhun, E.L. (2020) How Did Lomustine Become Standard of Care in Recurrentgliobl Astoma? Cancer Treatment Reviews, 87, 102029. &lt;br&gt;https://doi.org/10.1016/j.ctrv.2020.102029</mixed-citation></ref><ref id="hanspub.39107-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Alexander, B.M., Ba, S., Berger, M.S., et al. (2018) Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clinical Cancer Research, 24, 737-743. &lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-17-0764</mixed-citation></ref><ref id="hanspub.39107-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Friedman, H.S., Prados, M.D., Wen, P.Y., et al. (2009) Bevacizumab Alone and in Combination with Irinotecan in Recurrent Glioblastoma. Journal of Clinical Oncology, 27, 4733-4740. &lt;br&gt;https://doi.org/10.1200/JCO.2008.19.8721</mixed-citation></ref><ref id="hanspub.39107-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Wick, W., Gorlia, T., Bendszus, M., et al. (2017) Lomustine and Bevacizumab in Progressive Glioblastoma. The New England Journal of Medicine, 377, 1954-1963. &lt;br&gt;https://doi.org/10.1056/NEJMoa1707358</mixed-citation></ref><ref id="hanspub.39107-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, H., Wang, R., Yu, Y., et al. (2019) Glioblastoma Treatment Modalities besides Surgery. Journal of Cancer, 10, 4793-4806. &lt;br&gt;https://doi.org/10.7150/jca.32475</mixed-citation></ref><ref id="hanspub.39107-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Heimberger, A.B., Hlatky, R., Suki, D., et al. (2005) Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients. Clinical Cancer Research, 11, 1462-1466.  
&lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-04-1737</mixed-citation></ref><ref id="hanspub.39107-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Sasmita, A.O., Wong, Y.P. and Ling, A.P.K. (2018) Biomarkers and Therapeutic Advances in Glioblastoma Multiforme. Asia-Pacific Journal of Clinical Oncology, 14, 40-51. &lt;br&gt;https://doi.org/10.1111/ajco.12756</mixed-citation></ref><ref id="hanspub.39107-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Del Vecchio, C.A., Li, G. and Wong, A.J. (2012) Targeting EGF Receptor Variant III: Tumor-Specific Peptide Vaccination for Malignant Gliomas. Expert Review of Vaccines, 11, 133-144. &lt;br&gt;https://doi.org/10.1586/erv.11.177</mixed-citation></ref><ref id="hanspub.39107-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Swartz, A.M., Li, Q.J. and Sampson, J.H. (2014) Rindopepimut: A Promising Immunotherapeutic for the Treatment of Glioblastoma Multiforme. Immunotherapy, 6, 679-690. &lt;br&gt;https://doi.org/10.2217/imt.14.21</mixed-citation></ref><ref id="hanspub.39107-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Yagiz, K., Huang, T.T., Espinoza, F.L., et al. (2016) Toca 511 plus 5-Fluorocytosine in Combination with Lomustine Shows Chemotoxic and Immunotherapeutic Activity with No Additive Toxicity in Rodent Glioblastoma Models. Neuro-Oncology, 18, 1390-1401. &lt;br&gt;https://doi.org/10.1093/neuonc/now089</mixed-citation></ref><ref id="hanspub.39107-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Cloughesy, T.F., Landolfi, J., Hogan, D.J., Bloomfield, S., et al. (2016) Phase 1 Trial of Vocimagene Amiretrorepvec and 5-Fluorocytosine for Recurrent High-Grade Glioma. Science Translational Medicine, 8, 341-375.  
&lt;br&gt;https://doi.org/10.1126/scitranslmed.aad9784</mixed-citation></ref><ref id="hanspub.39107-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Crommentuijn, M.H.W., Kantar, R., Noske, D.P., et al. (2016) Systemically Administered AAV9-sTRAIL Combats Invasive Glioblastoma in a Patient-Derived Orthotopic Xenograft Model. Molecular Therapy Oncolytics, 3, 16017.  
&lt;br&gt;https://doi.org/10.1038/mto.2016.17</mixed-citation></ref><ref id="hanspub.39107-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Gray, S.J., Matagne, V., Bachaboina, L., et al. (2011) Preclinical Differences of Intravascular AAV9 Delivery to Neurons and Glia: A Comparative Study of Adult Mice and Nonhuman Primates. Molecular Therapy, 19, 1058-1069.</mixed-citation></ref><ref id="hanspub.39107-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Natsume, A. and Yoshida, J. (2008) Gene Therapy for High-Grade Glioma: Current Approaches and Future Directions. Cell Adhesion &amp; Migration, 2, 186-191. &lt;br&gt;https://doi.org/10.4161/cam.2.3.6278</mixed-citation></ref><ref id="hanspub.39107-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Hong, Y.K., Joe, Y.A., Yang, Y.J., et al. (2000) Potentials and Limitations of Adenovirus-p53 Gene Therapy for Brain Tumors. Journal of Korean Medical Science, 15, 315-322. &lt;br&gt;https://doi.org/10.3346/jkms.2000.15.3.315</mixed-citation></ref><ref id="hanspub.39107-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Stupp, R., Taillibert, S., Kanner, A., et al. (2017) Effect of Tumor-Treating Fields plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients with Glioblastoma: A Randomized Clinical Trial. JAMA, 318, 2306-2316. &lt;br&gt;https://doi.org/10.1001/jama.2017.18718</mixed-citation></ref><ref id="hanspub.39107-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Kirson, E.D., Gurvich, Z., Schneiderman, R., et al. (2004) Disruption of Cancer Cell Replication by Alternating Electric Fields. Cancer Research, 64, 3288-3295. &lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-04-0083</mixed-citation></ref><ref id="hanspub.39107-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Fabian, D., Eibl, G.P., Alnahhas, I., et al. (2019) Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review. Cancers (Basel), 11, 174. &lt;br&gt;https://doi.org/10.3390/cancers11020174</mixed-citation></ref><ref id="hanspub.39107-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Chinnaiyan, P., Won, M., Wen, P.Y., et al. (2018) A Randomized Phase II Study of Everolimus in Combination with Chemoradiation in Newly Diagnosed Glioblastoma: Results of NRG Oncology RTOG 0913. Neuro-Oncology, 20, 666-673. &lt;br&gt;https://doi.org/10.1093/neuonc/nox209</mixed-citation></ref><ref id="hanspub.39107-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Vasilev, A., Sofi, R., Rahman, R., et al. (2020) Using Light for Therapy of Glioblastoma Multiforme (GBM). Brain Sciences, 10, 75. &lt;br&gt;https://doi.org/10.3390/brainsci10020075</mixed-citation></ref><ref id="hanspub.39107-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Baptista, M.S., Cadet, J., Di Mascio, P., et al. (2017) Type I and Type II Photosensitized Oxidation Reactions: Guidelines and Mechanistic Pathways. Photochemistry and Photobiology, 93, 912-919. &lt;br&gt;https://doi.org/10.1111/php.12716</mixed-citation></ref><ref id="hanspub.39107-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Mahmoudi, K., Garvey, K.L., Bouras, A., et al. (2019) 5-Aminolevulinic Acid Photodynamic Therapy for the Treatment of High-Grade Gliomas. Journal of Neuro-Oncology, 141, 595-607. &lt;br&gt;https://doi.org/10.1007/s11060-019-03103-4</mixed-citation></ref><ref id="hanspub.39107-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Robertson, C.A., Evans, D.H. and Abrahamse, H. (2009) Photodynamic Therapy (PDT): A Short Review on Cellular Mechanisms and Cancer Research Applications for PDT. Journal of Photochemistry and Photobiology B: Biology, 96, 1-8. &lt;br&gt;https://doi.org/10.1016/j.jphotobiol.2009.04.001</mixed-citation></ref><ref id="hanspub.39107-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Schwartz, C., Ruhm, A., Tonn, J.-C., et al. (2015) Interstital Photodynamic Therapy of De-Novo Glioblastoma Multiforme WHO IV. Neuro-Oncology, 17, 214-220. &lt;br&gt;https://doi.org/10.1093/neuonc/nov235.25</mixed-citation></ref><ref id="hanspub.39107-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Stylli, S.S., Kaye, A.H., MacGregor, L., et al. (2005) Photodynamic Therapy of High Grade Glioma—Long Term Survival. Journal of Clinical Neuroscience, 12, 389-398. &lt;br&gt;https://doi.org/10.1016/j.jocn.2005.01.006</mixed-citation></ref><ref id="hanspub.39107-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Muller, P.J. and Wilson, B.C. (2006) Photodynamic Therapy of Brain Tumors—A Work in Progress. Lasers in Surgery and Medicine, 38, 384-389. &lt;br&gt;https://doi.org/10.1002/lsm.20338</mixed-citation></ref><ref id="hanspub.39107-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Akimoto, J., Haraoka, J. and Aizawa, K. (2012) Preliminary Clinical Report on Safety and Efficacy of Photodynamic Therapy Using Talaporfin Sodium for Malignant Gliomas. Photodiagnosis and Photodynamic Therapy, 9, 91-99.  
&lt;br&gt;https://doi.org/10.1016/j.pdpdt.2012.01.001</mixed-citation></ref><ref id="hanspub.39107-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Rosenthal, M.A., Kavar, B., Uren, S., et al. (2003) Promising Survival in Patients with High-Grade Gliomas Following Therapy with a Novel Boronated Porphyrin. Journal of Clinical Neuroscience, 10, 425-427.</mixed-citation></ref></ref-list></back></article>